RxDoctor Payments Data

Steven Gerhardt, MD

Neurology · Dallas, TXNPI 1972609766

Payments from drug & device makers

$9,038in general payments, 2019–2025

Across 450 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$735
  • Novartis$594
  • Genentech USA, Inc.$329
  • Acadia Pharmaceuticals Inc$317
  • Pfizer$314
  • plus $5K from 54 others

What the payments were for

  • Speaking & faculty fees$1081%
  • Food & beverage$8,93199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)77$1,407
UCB, Inc.27$735
Novartis39$594
Genentech USA, Inc.17$329
Acadia Pharmaceuticals Inc17$317
Pfizer18$314
AstraZeneca15$285
Eisai Inc.9$275
Lilly USA, LLC16$262
Biogen15$249
Teva Pharmaceuticals USA, Inc.9$209
Merz Pharmaceuticals, LLC6$208
Grifols USA, LLC9$190
Johnson & Johnson(2 entities)4$180
Amgen(2 entities)9$177
Vanda Pharmaceuticals Inc.5$171
CSL Behring9$168
Sunovion Pharmaceuticals Inc.11$156
Lundbeck LLC8$155
Bristol Myers Squibb8$149
Neurocrine Biosciences, Inc.7$145
Acorda Therapeutics, Inc7$135
Sanofi5$135
Immedica Pharma US, Inc.4$135
Amneal Pharmaceuticals LLC7$122
Adamas Pharmaceuticals, Inc.6$115
Merz North America, Inc.3$107
Argenx US, Inc.4$106
EMD Serono, Inc.6$96
Neurelis, Inc.4$88
Hospira, Inc.5$84
TG Therapeutics, Inc.4$82
Octapharma USA, Inc.3$76
Sumitomo Pharma America, Inc.3$70
Mallinckrodt Enterprises LLC3$68
Upsher-smith Laboratories LLC4$66
Catalyst Pharmaceuticals, Inc.3$58
Tanabe Pharma America, Inc.3$55
Supernus Pharmaceuticals, Inc.4$55
Ipsen Biopharmaceuticals, Inc2$51
Akcea Therapeutics, Inc.1$51
Averitas Pharma Inc.2$49
GE HealthCare3$48
Abbott2$44
Alnylam Pharmaceuticals Inc.2$34
Assertio Therapeutics, Inc.2$34
Avanir Pharmaceuticals, Inc.2$33
Scilex Pharmaceuticals Inc.2$31
Cycle Pharmaceuticals Inc1$29
Currax Pharmaceuticals LLC2$29
Jazz Pharmaceuticals Inc.1$26
Takeda Pharmaceuticals U.S.A., Inc.1$23
Impel Pharmaceuticals Inc.1$21
Vertical Pharmaceuticals, LLC1$21
Life Molecular Imaging Ltd1$20
Aquestive Therapeutics, Inc.1$19
Aprecia Pharmaceuticals, LLC1$18
Itamar Medical Inc1$17
Springworks Therapeutics, Inc.1$17
Otsuka America Pharmaceutical, Inc.1$17

How this compares

$9,038 in reported general payments places this provider in the 65th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$233,550
Medicare patients
616
Services billed
2,578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5013$198,814
Gamunex-CImmune Globul G/Gly/Iga Avg 4622$67,133
VimpatLacosamide11$20,253
Gabapentin61$1,101
Levetiracetam27$1,024
Oxcarbazepine13$750
Memantine Hcl14$431
Trazodone Hcl41$390
Donepezil Hcl20$257
Carbidopa-LevodopaCarbidopa/Levodopa11$254
Pregabalin22$195
Sertraline Hcl12$117
Prednisone14$44

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam$314$198,81413 claims
Grifols USA, LLCGamunex-C$190$67,13322 claims
UCB, Inc.Vimpat$735$20,25311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,246 neurology providers in Texas.

Other neurology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →